VYXEOS ® (Liposome-encapsulated combination of Daunorubicin and Cytarabine)

The FDA on August 3, 2017 granted regular approval to VYXEOS ® for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC), two types of AML having a poor prognosis. VYXEOS ® is a product of Jazz Pharmaceuticals.